Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PReDicT

Financiado

Cerrado

Predicting Response to Depression Treatment

The objective of the Predicting Response to Depression Treatment (PReDicT) project is to conduct clinical, health economic and commercial research to validate the clinical performance and to complete the pre-commercial development... ver más

30/11/2019

P1VITAL

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

P1VITAL LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-11-30

PHC-12-2015: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

P1VITAL

4.09M€ | Lider

P1VITAL PRODUCTS LIMITED

600.78K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PReDicT Predicting Response to Depression Treatment 71K€ Cerrado

DDBSD Diagnostic Test For The Differential Diagnosis of Bipolar Di... 71K€ Cerrado

PID2020-116187RB-I00 CAMBIO FIABLE Y CLINICAMENTE RELEVANTE DEL INVENTORY OF DEPR... 42K€ Cerrado

SACCSCAN SACCSCAN personalising clinical management of major psychi... 71K€ Cerrado

PLATOSCIENCE Personalized Neurostimulation Approach for the Treatment of... 71K€ Cerrado

PID2021-126291OA-I00 EFECTIVIDAD DE UNA INTERVENCION BIOPSICOSOCIAL ONLINE PARA M... 84K€ Cerrado

Duración del proyecto: 47 meses Fecha Inicio: 2015-12-10
Fecha Fin: 2019-11-30

Líder del proyecto

P1VITAL LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The objective of the Predicting Response to Depression Treatment (PReDicT) project is to conduct clinical, health economic and commercial research to validate the clinical performance and to complete the pre-commercial development of the P1vital PReDicT Test (formerly the eHealth P1vital® Oxford Emotional Test Battery (eH-ETB)), a novel medical device to improve the treatment and management of depression in clinical practice. On completion of the PReDicT project, the P1vital PReDicT Test will be ready for market launch. Depression is a common, serious and in some cases life‐threatening condition, affecting around 350 million people in the world and 11% of EU citizens suffer from depression at some point in their life. It takes 4-6 weeks after starting antidepressant treatment before a physician can detect whether the treatment is working, the majority of patients with depression do not respond to the first treatment they are prescribed and it can take several months before an effective treatment is identified. During this time a patients’ ability to work and function socially is severely impaired, and they can spend many weeks or months absent from work placing a substantial burden on the economy and healthcare resources. The P1vital PReDicT Test addresses this problem by identifying within 1 week of starting treatment whether an antidepressant is working or not which can significantly reduce the time required to identify an effective treatment. Patients benefit from this by returning to good mental health sooner. The aggregated economic cost of depression in the EU is €92 billion, amounting to 1% of the total European gross domestic product. It is estimated that the P1vital PReDicT Test has the potential to reduce these healthcare and economic costs by more than 10%. Thus the PReDicT project focuses on a patient-centric, enabling technology that not only improves efficiency and outcomes for patients but also significantly reduces socio-economic costs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores